Xenocor Pharmalab Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 18-07-2024
- Paid Up Capital ₹ 1.00 M
as on 18-07-2024
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 91.83%
(FY 2022)
- Profit 7.73%
(FY 2022)
- Ebitda 1.57%
(FY 2022)
- Net Worth 47.64%
(FY 2022)
- Total Assets 53.46%
(FY 2022)
About Xenocor Pharmalab
The Corporate was formerly known as Spill Containment Specialities Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Niranjana Chandappa and Ranganathaiah Chetan serve as directors at the Company.
- CIN/LLPIN
U29299KA2007PTC042079
- Company No.
042079
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Mar 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangalore, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Xenocor Pharmalab?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Niranjana Chandappa  | Director | 28-Mar-2022 | Current |
| Ranganathaiah Chetan | Director | 16-Mar-2023 | Current |
Financial Performance and Corporate Structure Insights of Xenocor Pharmalab.
Xenocor Pharmalab Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 91.83% increase. The company also saw a slight improvement in profitability, with a 7.73% increase in profit. The company's net worth Soared by an impressive increase of 47.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Xenocor Pharmalab?
In 2022, Xenocor Pharmalab had a promoter holding of 5.00% and a public holding of 95.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
East West Handling And Distribution Private LimitedActive 19 years 4 monthsNiranjana Chandappa is a mutual person
Avigna Learning Academy Private LimitedActive 3 years 7 monthsNiranjana Chandappa is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Xenocor Pharmalab?
Unlock and access historical data on people associated with Xenocor Pharmalab, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Xenocor Pharmalab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Xenocor Pharmalab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
